Trial Profile
A Phase Ib Study Evaluating the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Immunomodulatory Agents in Patients With Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Oct 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Guadecitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 01 Sep 2022 Results published in the Leukemia and Lymphoma
- 11 Mar 2020 Status changed from active, no longer recruiting to completed.
- 26 Aug 2019 Status changed from suspended to active, no longer recruiting.